| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | spautin-1 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.084 | 0.1 |